Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D3L-002 in Advanced Solid Tumors
NCT07667842Phase 1Recruiting
- Sponsor
- D3 Bio
- Start
- Jul 2026
- Primary completion
- Nov 2027
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of D3L-002 in solid tumor, sponsored by D3 Bio. Primary endpoints: Incidence and Severity of Treatment-Emergent Adverse Events and Treatment-Related Adverse Events, Change from Baseline in Hemoglobin and 17 more. Started Jul 2026; status: recruiting.
02
Drugs
D3L-002
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07667842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07667842.